- Market Capitalization, $K 127,335,408
- Shares Outstanding, K 2,504,138
- Annual Sales, $ 42,147 M
- Annual Income, $ 3,256 M
- 60-Month Beta 0.62
- Price/Sales 3.18
- Price/Cash Flow 11.88
- Price/Book 1.92
|Period||Period Low||Period High||Performance|
| || |
+0.64 (+1.27%)since 01/21/20
| || |
+3.68 (+7.80%)since 11/21/19
| || |
+9.52 (+23.03%)since 02/21/19
Emergent's (EBS) earnings lag estimates in Q4 while revenues surpass the mark.
AstraZeneca's (AZN) Q4 results were disappointing. European Commission approves Novartis (NVS) and Pfizer's (PFE) new drugs.
Amarin's (AMRN) fourth-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Sanofi (SNY) and J&J (JNJ) sign deals with BARDA, part of U.S. Department of Health and Human Services, for accelerated development of a vaccine for the newly found coronavirus.
Regeneron (REGN) announces positive two-year results from the phase III PANORAMA study on lead ophthalmology drug, Eylea.
Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.
Alnylam (ALNY) posts a wider-than-expected loss, while revenues beat estimates marginally in the fourth quarter of 2019.
Sanofi (SNY) reports mixed fourth-quarter results with strong Specialty Care and Vaccines sales but soft Consumer Healthcare sales
Regeneron (REGN) beats on Q4 earnings and sales on solid performance of ophthalmology drug, Eylea, and asthma drug, Dupixent.
Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.
|Advisorshares Doubleline Value Equity ETF|
|EAFE ESG Optimized Ishares MSCI ETF|
|Interm Govt/Credit Bond Ishares ETF|
|EAFE Value Ishares MSCI ETF|
|Ishares Genomics Immunology and Healthcare ETF|